Vascular hyporesponsiveness to angiotensin II in rats with CCl 4-induced liver cirrhosis

European Journal of Clinical Investigation

Volumn 39, Issue 10, 2009, Pages 906-913

  Hennenberg, M ^a,b   Trebicka, J ^a   Kohistani, A Z ^a   Heller, J ^a   Sauerbruch, T ^a  

^a UNIVERSITY OF BONN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Beta arrestin; Cirrhosis; Hyperdynamic circulation; Portal hypertension; Rho kinase; Vascular hypocontractility

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BETA ARRESTIN 2; CARBON TETRACHLORIDE; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RHO KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; IMMUNOPRECIPITATION; LIVER CIRRHOSIS; MALE; MUSCLE ISOMETRIC CONTRACTION; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; VASCULAR RING; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; AORTA; BLOTTING, WESTERN; CARBON TETRACHLORIDE; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; VASODILATION;

EID: 70349248249     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02181.x     Document Type: Article

References (34)

1. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008 57 : 1300 1314.
2. Wiest R. Splanchnic and systemic vasodilation: the experimental models. J Clin Gastroenterol 2007 41 : S272 87.
3. Rockey DC. Pharmacologic therapy for gastrointestinal bleeding due to portal hypertension and esophageal varices. Curr Gastroenterol Rep 2006 8 : 7 13.
4. Döhler KD, Meyer M. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal hemorrhage. Best Pract Res Clin Anaesthesiol 2008 22 : 335 350.
5. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006 43 : 385 394.
6. Sellars L, Shore AC, Mott V, Wilkinson R. The renin-angiotensin- aldosteron system in decompensated cirrhosis: its activity in relation to sodium balance. Q J Med 1985 56 : 485 496.
7. Moreau R, Lebrec D. Acute kidney injury: new concepts. Hepatorenal syndrome: the role of vasopressors. Nephron Physiol 2008 109 : 73 9.
8. Møller S, Bendtsen F, Henriksen JH. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. Scand J Gastroenterol 2006 41 : 451 458.
9. Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Hennenberg M et al. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int 2005 25 : 657 666.
10. Töx U, Steffen HM. Impact of inhibitors of the renin-angiotensin- aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem 2006 13 : 3649 3661.
11. Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Tsujimoto T et al. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr Med Chem 2007 14 : 2749 2754.
12. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006 130 : 838 854.
13. Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J. Vascular dysfunction in human and rats cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 2007 45 : 495 506.
14. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E et al. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006 55 : 1296 1305.
15. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 2008 47 : 1264 1276.
16. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999 104 : 1223 1233.
17. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009 157 : 258 270.
18. Heller J, Schepke M, Gehnen N, Molderings GJ, Müller A, Erhard J et al. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroernterology 1999 116 : 387 393.
19. Schepke M, Heller J, Paschke S, Thomas J, Wolff M, Neef M et al. Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism. Hepatology 2001 34 : 884 888.
20. Van de Casteele M, Sägesser H, Zimmermann H, Reichen J. Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver blood flow. Pharmacol Ther 2001 90 : 35 43.
21. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000 522 : 177 185.
22. Somlyo AP, Somlyo A. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003 83 : 1325 1358.
23. Gong MC, Gorenne I, Read P, Jia T, Nakamoto RK, Somlyo AV et al. Regulation by GDI of RhoA/Rho-kinase-induced Ca2+ sensitization of smooth muscle myosin II. Am J Physiol Cell Physiol 2001 281 : C257 69.
24. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 2005 15 : 356 363.
25. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001 53 : 1 24.
26. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002 115 : 455 465.
27. Thomas WG, Qian H. Arresting angiotensin type 1 receptors. Trends Endocrinol Metab 2003 14 : 130 136.
28. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 2007 69 : 511 534.
29. Brown MD, Sacks DB. Compartmentalised MAPK pathways. Handb Exp Pharmacol 2008 186 : 205 235.
30. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007 292 : C82 97.
31. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006 20 : 953 970.
32. Thomas WG, Qian H, Smith NJ. When 6 is 9: 'Uncoupled' AT1 receptors turn signalling on its head. Cell Mol Life Sci 2004 61 : 2687 2694.
33. DeFea K. β-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol 2007 153 : S298 309.
34. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by β-arrestins. Science 2005 308 : 512 517.